| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 10. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | andexanet alfa (Ondexxya®) |
| Formulation | 200 mg powder for solution for infusion |
| Reference number | 2409 |
| Indication | Treatment of adult patients treated with a direct factor Xa (Fxa) inhibitor (apixaban or rivaroxaban) when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding |
| Company | Alexion Pharma UK Ltd |
| BNF chapter | Nutrition & blood |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 06/06/2019 |
| NICE guidance | TA697: Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban |